Navigation Links
PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial
Date:3/10/2008

MIDLOTHIAN, Va., March 10 /PRNewswire/ -- PARI's LC STAR nebulizer and PRONEB Ultra II compressor are the exclusive delivery devices for Inspire Pharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a potential new cystic fibrosis treatment. PARI reusable nebulizers are considered the gold standard for clinical trials and are recommended in commercial sales including AstraZeneca's Pulmicort Respules, Sepracor's Xopenex and Brovana, Novartis' TOBI, Genentech's Pulmozyme, and DEY LP's Accuneb, Duoneb, and Perforomist.

"PARI has a strong track record of reliable and efficient, reproducible drug delivery, so it only makes sense that so many pharmaceutical companies look to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies."

Known as TIGER-2, Inspire's second pivotal Phase 3 clinical trial with denufosol tetrasodium inhalation solution is beginning enrollment in the U.S. and Canada with patients age 5 years and older. The use of standard CF maintenance therapies is permitted during the trial, and additional information is available at http://www.inspirepharm.com.

The combination of PARI's LC STAR nebulizer and PRONEB Ultra II compressor provides for a quick treatment with high efficiency and minimal medication waste.

It is hoped that denufosol could be the first early intervention therapy available to CF patients that affects an early step in the progression of the disease. Denufosol for the treatment of cystic fibrosis has been granted Fast Track designation and orphan drug status in the United States by the FDA and orphan drug designation in Europe by the European Medicines Agency (EMEA).

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufacturers the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.Pari.com


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... to develop sutezolid as effective response to infectious disease ... Alliance and the Medicines Patent Pool (MPP) announced a ... antibiotic drug candidate which demonstrated encouraging results in early ... in combination with other TB drugs and follows the ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017 /PRNewswire/ ... and the William Sansum Diabetes Center have established a ... affected by diabetes through enhanced research, education and care. ... cardiovascular disease bears a disproportionate weight on Latino families ... David Kerr , M.D., FRCPE, director of Innovation ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming of Christ, ... of published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation ... age ninety-one, he shares the Wisdom God bestowed upon him in this publication. ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria ... teeth the minimum two times a day that dentists recommend. The ramifications of improper oral ... of school and adults missing 164 million hours of work each year due to dental ...
Breaking Medicine News(10 mins):